These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33894670)

  • 1. PHF19 inhibition as a therapeutic target in multiple myeloma.
    Schinke CD; Bird JT; Qu P; Yaccoby S; Lyzogubov VV; Shelton R; Ling W; Boyle EM; Deshpande S; Byrum SD; Washam C; Mackintosh S; Stephens O; Thanendrarajan S; Zangari M; Shaughnessy J; Zhan F; Barlogie B; van Rhee F; Walker BA
    Curr Res Transl Med; 2021 Jul; 69(3):103290. PubMed ID: 33894670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PHF19 promotes multiple myeloma tumorigenicity through PRC2 activation and broad H3K27me3 domain formation.
    Ren Z; Ahn JH; Liu H; Tsai YH; Bhanu NV; Koss B; Allison DF; Ma A; Storey AJ; Wang P; Mackintosh SG; Edmondson RD; Groen RWJ; Martens AC; Garcia BA; Tackett AJ; Jin J; Cai L; Zheng D; Wang GG
    Blood; 2019 Oct; 134(14):1176-1189. PubMed ID: 31383640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insights into high-risk multiple myeloma from an analysis of the role of PHF19 in cancer.
    Ghamlouch H; Boyle EM; Blaney P; Wang Y; Choi J; Williams L; Bauer M; Auclair D; Bruno B; Walker BA; Davies FE; Morgan GJ
    J Exp Clin Cancer Res; 2021 Dec; 40(1):380. PubMed ID: 34857028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polycomb-like Protein 3 Induces Proliferation and Drug Resistance in Multiple Myeloma and Is Regulated by miRNA-15a.
    Yu T; Du C; Ma X; Sui W; Yu Z; Liu L; Zhao L; Li Z; Xu J; Wei X; Zhou W; Deng S; Zou D; An G; Tai YT; Tricot G; Anderson KC; Qiu L; Zhan F; Hao M
    Mol Cancer Res; 2020 Jul; 18(7):1063-1073. PubMed ID: 32312841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PHD finger protein 19 expression in multiple myeloma: Association with clinical features, induction therapy outcome, disease progression, and survival.
    Li Y; Gong J; Zhang L
    J Clin Lab Anal; 2021 Sep; 35(9):e23910. PubMed ID: 34390275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PHF19 mediated regulation of proliferation and invasiveness in prostate cancer cells.
    Jain P; Ballare C; Blanco E; Vizan P; Di Croce L
    Elife; 2020 Mar; 9():. PubMed ID: 32155117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulation of PHF19 inhibits cell growth and migration in gastric cancer.
    Wang H; Xu P; Sun G; Lv J; Cao J; Xu Z
    Scand J Gastroenterol; 2020 Jun; 55(6):687-693. PubMed ID: 32449434
    [No Abstract]   [Full Text] [Related]  

  • 8. PHF19 promotes the proliferation, migration, and chemosensitivity of glioblastoma to doxorubicin through modulation of the SIAH1/β-catenin axis.
    Deng Q; Hou J; Feng L; Lv A; Ke X; Liang H; Wang F; Zhang K; Chen K; Cui H
    Cell Death Dis; 2018 Oct; 9(11):1049. PubMed ID: 30323224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An H3K36 methylation-engaging Tudor motif of polycomb-like proteins mediates PRC2 complex targeting.
    Cai L; Rothbart SB; Lu R; Xu B; Chen WY; Tripathy A; Rockowitz S; Zheng D; Patel DJ; Allis CD; Strahl BD; Song J; Wang GG
    Mol Cell; 2013 Feb; 49(3):571-82. PubMed ID: 23273982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phf19 links methylated Lys36 of histone H3 to regulation of Polycomb activity.
    Ballaré C; Lange M; Lapinaite A; Martin GM; Morey L; Pascual G; Liefke R; Simon B; Shi Y; Gozani O; Carlomagno T; Benitah SA; Di Croce L
    Nat Struct Mol Biol; 2012 Dec; 19(12):1257-65. PubMed ID: 23104054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive Pan-Cancer Genomic Analysis Reveals PHF19 as a Carcinogenic Indicator Related to Immune Infiltration and Prognosis of Hepatocellular Carcinoma.
    Zhu ZY; Tang N; Wang MF; Zhou JC; Wang JL; Ren HZ; Shi XL
    Front Immunol; 2021; 12():781087. PubMed ID: 35069553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural basis for histone variant H3tK27me3 recognition by PHF1 and PHF19.
    Dong C; Nakagawa R; Oyama K; Yamamoto Y; Zhang W; Dong A; Li Y; Yoshimura Y; Kamiya H; Nakayama JI; Ueda J; Min J
    Elife; 2020 Sep; 9():. PubMed ID: 32869745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WDR26 and MTF2 are therapeutic targets in multiple myeloma.
    Sun F; Cheng Y; Riordan JD; Dupuy A; Dubois W; Pisano M; Dong J; Mock B; Zhan F; Hari P; Janz S
    J Hematol Oncol; 2021 Dec; 14(1):203. PubMed ID: 34876184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EWS/ETS-Driven Ewing Sarcoma Requires BET Bromodomain Proteins.
    Gollavilli PN; Pawar A; Wilder-Romans K; Natesan R; Engelke CG; Dommeti VL; Krishnamurthy PM; Nallasivam A; Apel IJ; Xu T; Qin ZS; Feng FY; Asangani IA
    Cancer Res; 2018 Aug; 78(16):4760-4773. PubMed ID: 29898995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polycomb Factor PHF19 Controls Cell Growth and Differentiation Toward Erythroid Pathway in Chronic Myeloid Leukemia Cells.
    García-Montolio M; Ballaré C; Blanco E; Gutiérrez A; Aranda S; Gómez A; Kok CH; Yeung DT; Hughes TP; Vizán P; Di Croce L
    Front Cell Dev Biol; 2021; 9():655201. PubMed ID: 33996816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tudor domains of the PRC2 components PHF1 and PHF19 selectively bind to histone H3K36me3.
    Qin S; Guo Y; Xu C; Bian C; Fu M; Gong S; Min J
    Biochem Biophys Res Commun; 2013 Jan; 430(2):547-53. PubMed ID: 23228662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs.
    Herviou L; Kassambara A; Boireau S; Robert N; Requirand G; Müller-Tidow C; Vincent L; Seckinger A; Goldschmidt H; Cartron G; Hose D; Cavalli G; Moreaux J
    Clin Epigenetics; 2018 Oct; 10(1):121. PubMed ID: 30285865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcription factor Phf19 positively regulates germinal center reactions that underlies its role in rheumatoid arthritis.
    Ning F; Wang C; Niu S; Xu H; Xia K; Wang N
    Am J Transl Res; 2018; 10(1):200-211. PubMed ID: 29423005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target.
    Agarwal P; Alzrigat M; Párraga AA; Enroth S; Singh U; Ungerstedt J; Österborg A; Brown PJ; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H
    Oncotarget; 2016 Feb; 7(6):6809-23. PubMed ID: 26755663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. microRNA-124a suppresses PHF19 over-expression, EZH2 hyper-activation, and aberrant cell proliferation in human glioma.
    Lu J; Ji H; Tang H; Xu Z
    Biochem Biophys Res Commun; 2018 Sep; 503(3):1610-1617. PubMed ID: 30131250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.